NO930513L - Oligonukleotid modulering av celleadhesjon - Google Patents

Oligonukleotid modulering av celleadhesjon

Info

Publication number
NO930513L
NO930513L NO93930513A NO930513A NO930513L NO 930513 L NO930513 L NO 930513L NO 93930513 A NO93930513 A NO 93930513A NO 930513 A NO930513 A NO 930513A NO 930513 L NO930513 L NO 930513L
Authority
NO
Norway
Prior art keywords
oligonucleotide
cell adhesion
treatment
methods
specifically hybridizable
Prior art date
Application number
NO93930513A
Other languages
English (en)
Other versions
NO930513D0 (no
Inventor
Clarence Frank Bennett
Christopher K Mirabelli
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of NO930513D0 publication Critical patent/NO930513D0/no
Publication of NO930513L publication Critical patent/NO930513L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3531—Hydrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

Sammensetninger og fremgangsmåter for behandling og diagnose av sykdommer for behandling ved modulering av syntese eller metabolisme av intercellulære adhesjonsmolekyler. Ifølge foretrukkede utførelsesformer blir oligonukleotlder og oligonukleotidanaloger skaffet tilveie og disse er spesifikk hybridiserbare med nukleinsyre som koder for intercellulær adhesjons- molekyl-1, vaskulær celleadhesjonsmolekyl-l og endotele leukocyttadhesjonsmolekyl-1 . Oligonukleotidet omfatter nukleotidenheter som er tilstrekkelig i Identitet og antall for å gjennomføre nevnte spesifikke hybridise- ring. I andre utførelsesformer er oligonukleotldene spesifikk hybridiserbare med et transkrlpsjonsini- tieringssete , et translasjonsinitiseringssete , 5'- utranslaterte sekvenser, 3 ' -utranslaterte sekvenser og intervenerende sekvenser. Fremgangsmåter for å behandle dyr som lider av sykdommen kan underkastes terapeutisk Intervenering ved å modulere celleadhesjonsprotelner med en oligonukleotid eller oligonukleotidanalog spesifikk hybridiserbar med RNA eller DNA som korre- sponderer til en av de foregående proteiner. Fremgangs- måter for behandling av sykdommer som responderer til moduleringscelleadhesjonsmolekyler blir beskrevet.
NO93930513A 1990-08-14 1993-02-12 Oligonukleotid modulering av celleadhesjon NO930513L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56728690A 1990-08-14 1990-08-14
PCT/US1991/005209 WO1992003139A1 (en) 1990-08-14 1991-07-23 Oligonucleotide modulation of cell adhesion

Publications (2)

Publication Number Publication Date
NO930513D0 NO930513D0 (no) 1993-02-12
NO930513L true NO930513L (no) 1993-04-01

Family

ID=24266532

Family Applications (1)

Application Number Title Priority Date Filing Date
NO93930513A NO930513L (no) 1990-08-14 1993-02-12 Oligonukleotid modulering av celleadhesjon

Country Status (14)

Country Link
EP (1) EP0544716B1 (no)
JP (1) JP2732544B2 (no)
KR (1) KR960009261B1 (no)
AT (1) ATE230023T1 (no)
AU (1) AU641539B2 (no)
BR (2) BR9106746A (no)
CA (1) CA2089563C (no)
DE (1) DE69133180T2 (no)
DK (1) DK0544716T3 (no)
ES (1) ES2188581T3 (no)
FI (1) FI930627A (no)
HU (1) HU217107B (no)
NO (1) NO930513L (no)
WO (1) WO1992003139A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449186B1 (en) 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
BR9307844A (pt) * 1992-01-31 1996-01-09 Univ California Processo para a formaçao de uma célula livre de antigenes para transplante célula livre de antigenes para transplante oligonucleotideo capaz de ligaçao a uma sequéncia nucleotidea antigene para transplante oligonucleotideo para utilizaçao na preparaçao de uma composiçao para o tratamento de células alvo orgao doador universal e processo para o tratamento de um individuo com uma doença autoimune
IL101600A (en) * 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
US5596090A (en) * 1992-07-24 1997-01-21 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human VCAM-1 RNA
NZ299210A (en) * 1992-09-02 2000-08-25 Isis Pharmaceuticals Inc Treating diseases characterised by changes in intercellular adhesion molecules using coding sequences hybridizable with those encoding proteins involved in synthesis of such molecules
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
JPH08113591A (ja) * 1994-10-14 1996-05-07 Taiho Yakuhin Kogyo Kk オリゴヌクレオチド及びこれを有効成分とする制癌剤
EP0831854A4 (en) * 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc OLIGONUCLEOTIDS WITH PHOSPHOROTHIOATE BINDINGS OF HIGH CHIRAL PURITY
DE10019252A1 (de) * 2000-04-18 2001-10-31 Klaus Karl Degitz Polydesoxyribonukleotide zur Hemmung der ICAM-1-Genexpression
CN104531843A (zh) * 2014-12-04 2015-04-22 杭州中翰金诺生物信息技术有限公司 肝癌诊断标志物黑素瘤细胞黏附分子及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006702A1 (en) * 1988-01-21 1989-07-27 Chemex Pharmaceuticals, Inc. Selective inhibition of gene expression by photoactivatable oligonucleotides
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)

Also Published As

Publication number Publication date
EP0544716A1 (en) 1993-06-09
CA2089563A1 (en) 1992-02-15
KR960009261B1 (en) 1996-07-16
JPH05508998A (ja) 1993-12-16
HU217107B (hu) 1999-11-29
CA2089563C (en) 2004-04-06
AU641539B2 (en) 1993-09-23
BR1100617A (pt) 2000-06-13
DE69133180T2 (de) 2003-07-24
FI930627A0 (fi) 1993-02-12
KR930701180A (ko) 1993-06-11
HUT68322A (en) 1995-06-28
DK0544716T3 (da) 2003-03-17
BR9106746A (pt) 1993-07-20
WO1992003139A1 (en) 1992-03-05
HU9300373D0 (en) 1993-05-28
NO930513D0 (no) 1993-02-12
JP2732544B2 (ja) 1998-03-30
ATE230023T1 (de) 2003-01-15
EP0544716A4 (en) 1994-09-14
FI930627A (fi) 1993-02-12
DE69133180D1 (de) 2003-01-30
ES2188581T3 (es) 2003-07-01
AU8313091A (en) 1992-03-17
EP0544716B1 (en) 2002-12-18

Similar Documents

Publication Publication Date Title
NO950800L (no) Oligonukleotidmodulering av celleadhesjon
EP0527818A4 (en) Oligonucleotide modulation of arachidonic acid metabolism
ATE244506T1 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
DE69331467D1 (de) Oligonukleotide modulation von protein kinase c
EP0714449A4 (en) OLIGONUCLEOTIDE MODULATION OF PROTEIN KINASE C
NO930513L (no) Oligonukleotid modulering av celleadhesjon
NO924140L (no) Oligonukleotidmodulering av arachidonsyre-metabolisme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application